• The article highlights the significant challenges facing the healthcare sector in Pakistan, particularly the lack of research and access to essential medicines. It notes that Pakistan's healthcare system is underfunded, with only 1% of the country's GDP allocated to the sector, leading to a shortage of resources and limited access to quality medical care for the majority of the population.

• One of the primary issues discussed is the lack of research and development in the pharmaceutical industry in Pakistan. The article states that the country's pharmaceutical industry is heavily reliant on imported active pharmaceutical ingredients (APIs), which makes the sector vulnerable to global supply chain disruptions and price fluctuations. This lack of local research and production capacity hampers the development of affordable and accessible medicines for the Pakistani population.

• The article also highlights the challenge of ensuring the availability and affordability of essential medicines in Pakistan. It notes that many essential drugs are not readily available in the market, and when they are, they are often priced beyond the reach of the common people. This issue is exacerbated by the lack of robust regulatory frameworks and oversight, which allows for the proliferation of substandard and counterfeit medicines in the market.